← Aurinia Pharmaceuticals Inc.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income From Continuing Operations — — — — — — ($108.2m) ($78.0m) $5.8m $287.2m
Net Income (Loss) Attributable to Parent — — — — ($102.7m) ($181.0m) ($108.2m) ($78.0m) $5.8m $287.2m
Depreciation, Depletion and Amortization — — — — $82k $663k $2.7m $11.6m $19.4m $19.4m
Depreciation — — — — $82k $663k $629k $606k $600k $600k
Amortization of Intangible Assets $1.5m $1.4m $1.5m $1.4m $1.3m $2.1m $2.1m $1.7m $900k $800k
Amortization Of Securities — — — — — — ($1.6m) ($12.1m) ($12.7m) ($10.2m)
Depreciation Amortization Depletion — — — — — — $2.7m $11.6m $19.4m $19.4m
Deferred Income Tax Expense (Benefit) — — — — $0 $0 $0 $0 — ($176.2m)
Deferred Income Tax — — — — — — — $0 $0 ($176.2m)
Deferred Tax — — — — — — — $0 $0 ($176.2m)
Share-based Payment Arrangement, Noncash Expense — — — — $17.5m $31.2m $32.3m $45.3m $31.6m $14.7m
Payment, Tax Withholding, Share-based Payment Arrangement — — — — — — — — $6.1m $9.8m
Adjustments For Share-Based Payments $1.4m $4.2m $6.9m $7.4m — — — — — —
Share-based Payment Arrangement, Expense — — — — $17.5m $31.2m $32.3m $45.3m $31.6m $14.7m
Asset Impairment Charge — — — — — — $3.6m $916k $0 $0
Income Tax Expense (Benefit) — — — — ($94k) $760k $1.8m $551k $1.7m ($173.0m)
Interest Expense Nonoperating — — — — — — — — $4.8m $4.3m
Changes in operating assets and liabilities:
Additional Financial Items
Increase (Decrease) in Inventories — — — — $13.9m $5.6m $9.1m $15.9m ($477k) $6.5m
Increase (Decrease) in Accounts Payable — — — — — — — — $860k ($1.9m)
Proceeds from Stock Options Exercised $107k $3.9m $943k $13.7m $6.6m $24.0m $2.4m $4.9m $8.2m $14.2m
Adjustments For Decrease Increase In Trade Account Receivable ($39k) ($23k) ($108k) ($151k) — — — — — —
Adjustments For Increase Decrease In Trade Account Payable $2.5m $2.2m ($888k) $4.1m — — — — — —
General and Administrative Expense $7.0m $12.1m $13.7m $22.2m $96.0m $171.4m $196.4m $195.0m $172.0m $101.8m
Increase Decrease In Working Capital ($1.5m) ($1.7m) $6.0m ($2.1m) — — — — — —
Interest Received Classified As Operating Activities $34k $973k $2.1m $2.6m — — — — — —
Inventory Write-down — — — — — — $3.6m $916k $0 $0
Investment Income, Interest — — — — — — — — $17.0m $13.6m
Operating Expenses — — — — $154.4m — — — $239.8m $178.1m
Payments Of Lease Liabilities Classified As Financing Activities — — — ($127k) — — — — — —
Purchase Of Intangible Assets Classified As Investing Activities $10k $0 $45k $17k — — — — — —
Restructuring Costs — — — — — — — — $23.1m $1.6m
Beginning Cash Position — — — — — — $231.9m $94.2m $48.9m $83.4m
Cash Flow From Continuing Financing Activities — — — — — — $2.4m ($5.1m) ($49.1m) ($106.1m)
Cash Flow From Continuing Investing Activities — — — — — — ($60.6m) ($6.7m) $39.3m ($32.8m)
Change In Account Payable — — — — — — ($792k) $1.2m $860k ($1.9m)
Change In Accrued Expense — — — — — — $1.5m $12.2m $13.3m ($4.7m)
Change In Inventory — — — — — — ($9.1m) ($15.9m) $477k ($6.5m)
Change In Other Current Assets — — — — — — ($363k) ($16k) $31k $730k
Change In Other Current Liabilities — — — — — — ($652k) ($673k) ($750k) ($802k)
Change In Other Working Capital — — — — — — $3.0m $3.8m $5.8m $3.7m
Change In Payable — — — — — — ($792k) $1.2m $860k ($1.9m)
Change In Payables And Accrued Expense — — — — — — $699k $13.4m $14.2m ($6.5m)
Change In Prepaid Assets — — — — — — ($2.4m) $4.4m ($1.8m) $5.5m
Change In Receivables — — — — — — $1.9m ($10.6m) ($12.5m) ($4.9m)
Change In Working Capital — — — — — — ($6.8m) ($5.6m) $5.4m ($8.8m)
Changes In Account Receivables — — — — — — $1.9m ($10.6m) ($12.5m) ($4.9m)
Changes In Cash — — — — — — ($137.7m) ($45.3m) $34.6m ($3.2m)
End Cash Position — — — — — — $94.2m $48.9m $83.4m $80.2m
Financing Cash Flow — — — — — — $2.4m ($5.1m) ($49.1m) ($106.1m)
Free Cash Flow — — — — — — ($79.8m) ($34.2m) $44.1m $135.4m
Investing Cash Flow — — — — — — ($60.6m) ($6.7m) $39.3m ($32.8m)
Issuance Of Capital Stock — — — — — $196.7m $0 $0 — —
Net Foreign Currency Exchange Gain Loss — — — — — — $0 $5.9m ($5.9m) $9.7m
Net Intangibles Purchase And Sale — — — — — ($1.2m) $0 $0 — —
Net PPE Purchase And Sale — — — — — — ($292k) ($718k) ($281k) ($252k)
Operating Gains Losses — — — — — — — $5.9m ($5.9m) $9.7m
Other Non Cash Items — — — — — — ($1.6m) ($1.5m) $788k ($200k)
Proceeds From Stock Option Exercised — — — — — — $3.5m $7.2m $9.3m $14.9m
Purchase Of Intangibles — — — — — ($1.2m) $0 $0 — —
Purchase Of PPE — $25k $30k $87k — — ($292k) ($718k) ($281k) ($252k)
Repurchase Of Capital Stock — — — — — — $0 $0 ($40.2m) ($98.2m)
Stock Based Compensation — — — — — — $32.3m $45.3m $31.6m $14.7m
Profit or Loss ($23.3m) ($70.8m) ($64.1m) ($123.8m) — — — — — —
Other Operating Income (Expense), Net — — — — $6.8m ($574k) $1.5m ($8.4m) $4.3m ($9.5m)
Net Cash Provided by (Used in) Operating Activities ($18.7m) ($41.2m) ($51.6m) ($63.5m) ($69.9m) ($157.7m) ($79.5m) ($33.5m) $44.4m $135.7m
Cash flows from investing activities:
Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities $19k $0 $20k $159k — — — — — —
Capital Expenditure — — — — — — ($292k) ($718k) ($281k) ($252k)
Capital Expenditure Reported — — — — — ($6k) $0 — — —
Net Investment Purchase And Sale — — — — — — ($59.7m) $5.9m $39.6m ($32.5m)
Purchase Of Investment — — — — — — ($524.0m) ($523.5m) ($545.8m) ($526.6m)
Sale Of Investment — — — — — — $464.3m $529.4m $585.4m $494.1m
Net Other Investing Changes — — — — — ($17.8m) ($663k) ($11.9m) ($43k) —
Net Cash Provided by (Used in) Investing Activities $10.0m ($8.0m) ($66k) $7.8m ($158.2m) ($103.9m) ($60.6m) ($6.7m) $39.3m ($32.8m)
Cash flows from financing activities:
Net Issuance Payments Of Debt — — — — — — $0 ($10.0m) ($12.0m) ($13.1m)
Net Long Term Debt Issuance — — — — — — $0 ($10.0m) ($12.0m) ($13.1m)
Long Term Debt Payments — — — — — — $0 ($10.0m) ($12.0m) ($13.1m)
Repayment Of Debt — — — — — — $0 ($10.0m) ($12.0m) ($13.1m)
Proceeds from Issuance of Common Stock — — — — $187.7m $196.7m $0 $0 $1.1m $756k
Common Stock Issuance — — — — — $196.7m $0 $0 — —
Net Common Stock Issuance — — — — — — $0 $0 ($40.2m) ($98.2m)
Payments for Repurchase of Common Stock — — — — — — — — $40.2m $98.2m
Common Stock Payments — — — — — — $0 $0 ($40.2m) ($98.2m)
Net Other Financing Charges — — — — — — ($1.0m) ($2.3m) ($6.1m) ($9.8m)
Net Cash Provided by (Used in) Financing Activities $42.6m $175.2m $4.0m $243.7m $194.4m $221.1m $2.4m ($5.1m) ($49.1m) ($106.1m)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $33.9m $126.0m ($47.7m) $188.1m ($33.7m) ($40.5m) ($137.7m) ($45.3m) $34.6m ($3.2m)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents — — — — $272.4m $231.9m $94.2m $48.9m $83.4m $80.2m
Supplemental disclosure of cash flow information:
Change In Cash Supplemental As Reported — — — — — — ($137.7m) ($45.3m) $34.6m ($3.2m)
Interest Paid Supplemental Data — — — — — $257k $2.0m — — —
Income Taxes Paid, Net — — — — — — $2.0m $496k $2.2m $2.8m

Data sourced from SEC EDGAR 10-K filings via EdgarTools. Amounts are shown in USD as reported in each fiscal year filing.